Open Your FREE Demat Account Now!

N/A
indicator

Nifty Midcap 50

1D
1M
3M
6M
1Y
5Y
empty graph

Nifty Midcap 50 Performance

Low

₹17,672.15

High

₹17,891.95

52 Week Range

Low

₹14,804.55

High

₹18,500.95

Previous Close ₹17,753.60
Day's Range ₹17,672.15 - ₹17,891.95
Open ₹17,753.40
52 Week Range ₹14,804.55 - ₹18,500.95
Volume 41,82,87,780

Nifty Midcap 50 Companies

Company Name LTP (₹) Change (₹) Sector
Dabur India Ltd. 383.30 Arrow 0.70 (0.18%) FMCG
Bharat Heavy Electricals Ltd. 431.20 Arrow -0.80 (-0.19%) Capital Goods
Hindustan Petroleum Corporation Ltd. 390.60 Arrow -9.55 (-2.39%) Crude Oil
Hero MotoCorp Ltd. 5342.00 Arrow -3.00 (-0.06%) Automobile & Ancillaries
Lupin Ltd. 2015.00 Arrow -8.40 (-0.42%) Healthcare
Max Financial Services Ltd. 1375.00 Arrow 72.00 (5.53%) Finance
The Federal Bank Ltd. 362.50 Arrow 0.90 (0.25%) Bank
Ashok Leyland Ltd. 173.95 Arrow 0.05 (0.03%) Automobile & Ancillaries
Bharat Forge Ltd. 1760.00 Arrow 11.40 (0.65%) Automobile & Ancillaries
The Indian Hotels Company Ltd. 882.00 Arrow 9.00 (1.03%) Hospitality

All Indices

Index Name Market Value 52W High 52W Low
Nifty 50 25299.35 26373.20 22179.90
Nifty IT 32163.55 40301.40 25699.10
Nifty Next 50 73481.25 75000.40 59896.10
NIFTY50 USD Index 9328.45 10443.40 7839.85
Nifty Bank 61518.5 61764.85 49954.85
NIFTY Midcap 100 62039.0 64450.90 52032.85
Nifty 500 23865.8 24144.20 20385.65
Nifty Midcap 50 17884.95 18500.95 14804.55
Nifty 100 26254.15 26975.15 22720.45
Nifty FMCG 46838.5 55897.55 42006.00

Latest News

Nov
12
2026
EQUITY Posted on Nov 12th 2026

Lupin informs about press release

Lupin has informed that it enclosed a Press Release titled ‘Lupin Announces European Launch of Biosimilar Ranibizumab‘.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
12
2026
EQUITY Posted on Nov 12th 2026

Federal Bank informs about allotment under ESOP

Federal Bank has infromed that Federal Bank allotments have been made after payment of money by the allottees: Allotment of 8,300 (Eight Thousand Three Hundred only) Equity Shares with face value of Rs 2 each of the Bank to the Option Grantees upon exercise of stock options under ESOS 2010 Scheme on November 12, 2026; Allotment of 58,198 (Fifty-Eight Thousand One Hundred and Ninety-Eight only) Equity Shares with face value of Rs 2 each of the Bank to the Option Grantees upon exercise of stock options under ESOS 2017 Scheme on November 12, 2026; Allotment of 4,470 (Four Thousand four hundred and seventy only) Equity Shares with face value of Rs 2 each of the Bank to the Option Grantees upon exercise of stock options under ESIS 2023 Scheme on November 12, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
12
2026
EQUITY Posted on Nov 12th 2026

NMDC informs about newspaper publication

In accordance with SEBI Circular no. SEBI/HO/38/13/11(2)2026-MIRSDPODII/3750/2026 dated January 30, 2026, NMDC has informed that a special window has been opened for Transfer and Dematerialization (Demat) of physical securities for a period of one year from February 05, 2026 to February 04, 2027. Pursuant to the aforesaid circular, it has attached copies of the newspaper publication published in English (Financial Express) and in Telugu (Vaartha) newspapers. This information is also being uploaded on the Company’s Website under Investor Section –Dividend and Shares.

The above information is a part of company’s filings submitted to BSE.

Read More
Nov
11
2026
EQUITY Posted on Nov 11th 2026

Aurobindo Pharma informs about unaudited financial results

Aurobindo Pharma has informed that it enclosed the transcript of the said earnings call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026 and the same is being uploaded on the website of the Company and is available at the following web link. https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-calltranscripts.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
11
2026
EQUITY Posted on Nov 11th 2026

Aurobindo Pharma informs about updates

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected Unit-II, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Gaddapotharam, Industrial Development Area - Kazipally Industrial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana from September 7th to September 15th, 2026. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). FDA has concluded that this inspection is closed under 21 CFR 20.64(d)(3).

The above information is a part of company’s filings submitted to BSE. 

Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Frequently Asked Questions

What is the Previous Close of MIDCAP50 index?

The previous close of MIDCAP50 index is ₹17884.95 as of 2026-11-12.

The total volume of MIDCAP50 index is 418287780.00 as of 2026-11-12.

The percentage change in value of MIDCAP50 index is 0.74% as of 2026-11-12.

The absolute increase in MIDCAP50 index value since the previous trading day is ₹131.35 as of 2026-11-12.

A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.

View More
Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore